Skip to main content
Discover what's not being covered
Published • loading... • Updated

Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $950.00 Price Target at JPMorgan Chase & Co.

Summary by MarketBeat
JPMorgan Chase & Co. upped their target price on Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the company an "overweight" rating in a report on Tuesday.

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

MarketBeat broke the news in Sioux Falls, United States on Tuesday, October 6, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal